retatrutide clinical trials results New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats retatrutide peptide | peptidesskin

Just as healthy food choices may increase GLP-1 levels, so can exercise

Similar to tirzepatide, retatrutides activation of GLP-1 and GIP receptors promotes insulin secretion, decelerates digestion, and reduces appetite, contributing to notable weight loss [6, 7, 8]

Phase 3 trials typically enroll thousands

In patients with DM2 the incretin response is diminished, but the insulinotropic effect of GLP-1 is conserved.28 Under normal conditions GLP-1 has a short half-life (approximately 2 min), as it is rapidly degraded by dipeptidylpeptidase 4, so GLP-1 analogues resistant to this enzyme have been developed for the treatment of DM2.29 arGLP-1: glucagon-like peptide 1 receptor agonist

For patients who simply cannot or will not inject, however, the comparison is irrelevant

Treatment persistence data further underscores this concern